Launch One Acquisition CORP Form 4 insider transactions

Launch One Acquisition Corp. secured up to $1 million in working capital from its sponsor to fund operations and business combination efforts, incurring significant debt costs.

Minovia Therapeutics announced two new U.S. patents, strengthening its mitochondrial augmentation therapy platform for primary mitochondrial and renal diseases.

Minovia Therapeutics, set to merge with Launch One Acquisition Corp., announced a $350,000 grant from Countdown for a Cure Foundation to develop novel mitochondrial blood-based biomarkers.

Minovia Therapeutics announced positive interim Phase 2 trial results for MNV-201 in Pearson Syndrome, showing a favorable safety profile and preliminary efficacy signals, alongside progress towards a business combination with Launch One Acquisition Corp.

Launch One Acquisition Corp. has entered into a definitive Business Combination Agreement with Minovia Therapeutics Ltd., an Israeli mitochondrial therapy company, which will result in Minovia becoming a publicly traded company on Nasdaq through a new parent entity, Mito US One Ltd. (Pubco).

Minovia Therapeutics announced that its lead investigational compound, MNV-201, received both Fast Track and Rare Pediatric Disease Designations from the FDA for the treatment of Pearson Syndrome, potentially accelerating its market entry and offering significant financial benefits.

Launch One Acquisition Corp., a SPAC, has entered into a definitive business combination agreement with Minovia Therapeutics Ltd., an Israeli clinical-stage biotechnology company, to create a publicly traded entity focused on mitochondrial augmentation technology.

Barclays PLC reports it is no longer subject to Section 16 reporting requirements due to the unwind of certain stock borrow and repurchase transaction activity that did not create a pecuniary interest in the securities of Launch One Acquisition Corp.

Barclays PLC reports it is no longer subject to Section 16 reporting requirements due to the unwind of certain stock borrow and repurchase transaction activity.